37 Recruiting Studies Using Apalutamide
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Apalutamide
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
📍 Clinical Research Facility — Homewood, Alabama
Prostate Cancer
View Study & Checklist ➔Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
📍 Cancer Center at Saint Joseph's — Phoenix, Arizona
Prostate Adenocarcinoma
View Study & Checklist ➔Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
📍 OHSU Knight Cancer Institute — Portland, Oregon
Castration-Sensitive Prostate Carcinoma
View Study & Checklist ➔An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
📍 Clinical Research Facility — Homewood, Alabama
Prostatic Neoplasms
View Study & Checklist ➔A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
📍 Clinical Research Facility — Birmingham, Alabama
Prostatic Neoplasms
View Study & Checklist ➔Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Metastatic Castration-Resistant Prostate Carcinoma
View Study & Checklist ➔Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
📍 Research Site — Detroit, Michigan
Metastatic Prostate Cancer
View Study & Checklist ➔An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
📍 Clinical Research Facility — Phoenix, Arizona
Prostatic Neoplasms
View Study & Checklist ➔Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Prostate Cancer
View Study & Checklist ➔Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Metastatic Prostate Adenocarcinoma
View Study & Checklist ➔A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
📍 UC San Diego Moores Cancer Center — La Jolla, California
Prostatic Neoplasms
View Study & Checklist ➔Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Prostate Adenocarcinoma
View Study & Checklist ➔A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
📍 Arizona Urology Specialists — Tucson, Arizona
Prostatic Neoplasms
View Study & Checklist ➔ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
📍 UC San Diego Moores Cancer Center — La Jolla, California
Metastatic Prostate Cancer
View Study & Checklist ➔Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Castration Levels of Testosterone
View Study & Checklist ➔Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
📍 Fairbanks Memorial Hospital — Fairbanks, Alaska
Prostate Adenocarcinoma
View Study & Checklist ➔Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
📍 University of Chicago — Chicago, Illinois
Prostate Cancer
View Study & Checklist ➔Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
📍 M D Anderson Cancer Center — Houston, Texas
Prostate Adenocarcinoma
View Study & Checklist ➔A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
📍 Urology Centers Of Alabama — Homewood, Alabama
Metastatic Castrate-sensitive Prostate Cancer
View Study & Checklist ➔Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Prostate Carcinoma
View Study & Checklist ➔Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
📍 Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
Recurrent Prostate Carcinoma
View Study & Checklist ➔Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
📍 VA Greater Los Angeles Healthcare System — Los Angeles, California
Metastatic Cancer
View Study & Checklist ➔Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
📍 START Los Angeles — Los Angeles, California
Castration-Resistant Prostate Cancer (CRPC)
View Study & Checklist ➔A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
📍 Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company — Cleveland, Ohio
Prostatic Neoplasms
View Study & Checklist ➔Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
📍 City of Hope — Duarte, California
Castration-resistant Prostate Cancer
View Study & Checklist ➔A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
📍 Florida Cancer Specialists — Sarasota, Florida
Metastatic Castration-resistant Prostate Neoplasms
View Study & Checklist ➔Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
📍 University of California Davis — Sacramento, California
Prostate Cancer
View Study & Checklist ➔AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
📍 Research Site — Dothan, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Prostate Adenocarcinoma
View Study & Checklist ➔Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Biochemically Recurrent Prostate Carcinoma
View Study & Checklist ➔Study of ORIC-944 in Patients With Metastatic Prostate Cancer
📍 Rocky Mountain Cancer Center — Colorado Springs, Colorado
Metastatic Prostate Cancer
View Study & Checklist ➔Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Prostate Carcinoma
View Study & Checklist ➔Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Prostate Cancer (Adenocarcinoma)
View Study & Checklist ➔PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
📍 Banner MD Anderson — Gilbert, Arizona
Androgen Axis Suppression
View Study & Checklist ➔Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Castration-Sensitive Prostate Carcinoma
View Study & Checklist ➔A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
📍 University of Colorado Anschutz Medical Campus — Aurora, Colorado
Prostatic Neoplasms
View Study & Checklist ➔Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
📍 Mayo Clinic in Arizona — Phoenix, Arizona
Recurrent Castration-Sensitive Prostate Carcinoma
View Study & Checklist ➔